Cargando…

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

INTRODUCTION: Until recently, systemic chemotherapy was the only option for treating bladder cancer and outcomes remained dismal. After a long gap of no progress for 40 years, immuno-therapy with checkpoint inhibitors (PDL1 and PD1) has revolutionized the treatment paradigm of bladder cancer, with f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stenehjem, David D, Tran, Dao, Nkrumah, Michael A, Gupta, Shilpa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157986/ https://www.ncbi.nlm.nih.gov/pubmed/30275703 http://dx.doi.org/10.2147/OTT.S135157

Ejemplares similares

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
por: Safi, Mohammed, et al.
Publicado: (2020)

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction
por: Patil, Sachin P., et al.
Publicado: (2022)

m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent
por: Kong, Jianqiu, et al.
Publicado: (2022)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer
por: Zhou, Lang, et al.
Publicado: (2022)

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report
por: Wang, Jianzheng, et al.
Publicado: (2021)

Retracted: Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis
por: Jin, Yao, et al.
Publicado: (2022)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

Is a Triggering Role or a Causative Role of PD-1/PDL-1 Inhibitors in the Development of Paraneoplastic Dermatomyositis?
por: Starace, Michela, et al.
Publicado: (2022)

Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review
por: Tavares, Dione Fernandes, et al.
Publicado: (2021)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
por: Świderska, Janina, et al.
Publicado: (2021)

A Diagnostic of Acquired Hemophilia Following PD1/PDL1 Inhibitors in Advanced Melanoma: The Experience of Two Patients and a Literature Review
por: Gidaro, Antonio, et al.
Publicado: (2022)

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer
por: Winer, Arthur, et al.
Publicado: (2019)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
por: Jiang, Qi, et al.
Publicado: (2022)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials
por: Parmar, Kanak, et al.
Publicado: (2022)

Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis
por: Dhupkar, Pooja M, et al.
Publicado: (2015)

The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis
por: Chang, Chih-Hao, et al.
Publicado: (2021)

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
por: Luo, Kunpeng, et al.
Publicado: (2022)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment
por: Filippova, Natalia, et al.
Publicado: (2018)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
por: Yin, Huanhuan, et al.
Publicado: (2020)

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer
por: Ye, Qing, et al.
Publicado: (2021)

The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer
por: AGHBASH, PARISA SHIRI, et al.
Publicado: (2023)

Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
por: Caldwell, Charles, et al.
Publicado: (2017)

Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity
por: Garo, Lucien P., et al.
Publicado: (2019)

MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway
por: Zhang, Yinghui, et al.
Publicado: (2020)

Anion binding properties of a hollow PdL-cage
por: Timmer, Brian J. J., et al.
Publicado: (2021)

The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials
por: Li, Fei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4p961dhilog2udlmbb7c3sm43s